Rocket Pharmaceuticals officer proposes 677-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. (RCKT) is identified as the issuer in a Form 144 notice for a proposed sale of 677 common shares for Wilson Martin’s account; Wilson Martin is identified as an officer. The notice lists an aggregate market value of $1,474.84 and an approximate sale date of November 18, 2026.
The shares were acquired through restricted stock vesting on November 16, 2026, as compensation. The notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Key Figures
Key Terms
Restricted Stock Vesting financial
vested equity award distribution financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.